



February 18, 2015

## **Ardelyx to Report Fourth Quarter and Full Year 2014 Financial Results on February 25th, 2015**

FREMONT, Calif., Feb. 18, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report its financial results for fourth quarter and full year ended December 31, 2014, on Wednesday, February 25, 2015. Following the announcement, the Ardelyx management team will host a live conference call and webcast at 4:30pm ET to review the Company's financial results and provide a business update.



The live webcast can be accessed by visiting the investor section of Ardelyx's website at [ir.ardelyx.com](http://ir.ardelyx.com). Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the conference call. The conference ID number for the live call will be 89320171. Following the webcast, an archived version of the call will be available until March 11, 2015.

### **About Ardelyx, Inc.**

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor. Ardelyx formed a collaborative partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. In addition to tenapanor, the Company has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in CKD-5D, a program licensed to Sanofi, and independently is advancing several additional research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at [www.ardelyx.com](http://www.ardelyx.com).

Logo - <http://photos.prnewswire.com/prnh/20140619/119451>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-full-year-2014-financial-results-on-february-25th-2015-300037428.html>

SOURCE Ardelyx, Inc.

News Provided by Acquire Media